Aurinia Pharmaceuticals (AUPH) News Today $7.92 +0.10 (+1.21%) Closing price 03:59 PM EasternExtended Trading$7.86 -0.06 (-0.76%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Aurinia Pharmaceuticals: There's Still Time For Sales GrowthFebruary 21 at 4:28 PM | seekingalpha.comAurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025February 20 at 4:21 PM | financialpost.comAurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025February 20 at 4:21 PM | financialpost.comAurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025February 20 at 4:05 PM | businesswire.comAurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded to "Buy" Rating by StockNews.comFebruary 20 at 3:01 AM | americanbankingnews.comStockNews.com Downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) to BuyStockNews.com downgraded Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Wednesday.February 19 at 2:18 AM | marketbeat.comAurinia Pharmaceuticals (AUPH) Projected to Post Earnings on ThursdayAurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing earnings before the market opens on Thursday, February 20, Financial Modeling Prep reports.February 18 at 3:32 AM | marketbeat.comXBiotech (NASDAQ:XBIT) vs. Aurinia Pharmaceuticals (NASDAQ:AUPH) Head-To-Head AnalysisFebruary 18 at 1:14 AM | americanbankingnews.comShort Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Expands By 25.5%Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 9,390,000 shares, an increase of 25.5% from the January 15th total of 7,480,000 shares. Based on an average trading volume of 1,430,000 shares, the days-to-cover ratio is currently 6.6 days.February 15, 2025 | marketbeat.comCompagnie Lombard Odier SCmA Cuts Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Compagnie Lombard Odier SCmA lowered its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 87.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,000 shares of the biotechnology coFebruary 15, 2025 | marketbeat.comAurinia Pharmaceuticals (AUPH) to Release Quarterly Earnings on ThursdayAurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing earnings before the market opens on Thursday, February 20, Financial Modeling Prep reports.February 13, 2025 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Shares Cross Below 50-Day Moving Average - What's Next?Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 50 Day Moving Average - Should You Sell?February 11, 2025 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Cut to Buy at StockNews.comFebruary 11, 2025 | americanbankingnews.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Rating Lowered by StockNews.comStockNews.com downgraded Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday.February 10, 2025 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Sees Large Increase in Short InterestAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 7,480,000 shares, an increase of 29.2% from the December 31st total of 5,790,000 shares. Based on an average daily trading volume, of 1,410,000 shares, the days-to-cover ratio is presently 5.3 days.February 1, 2025 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC lowered its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 88.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 62,564 shares of theFebruary 1, 2025 | marketbeat.comIs Aurinia Pharmaceuticals Poised for Growth in the Biotech Space?January 14, 2025 | stocknews.comBarclays PLC Increases Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Barclays PLC lifted its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 187.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 219,331 shares of the biotechnology compaJanuary 12, 2025 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded by StockNews.com to Strong-Buy RatingStockNews.com upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday.January 9, 2025 | marketbeat.comFranklin Resources Inc. Sells 75,024 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Franklin Resources Inc. cut its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 78.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,253 shares of the biotechnology company's stJanuary 3, 2025 | marketbeat.comBarclays PLC Buys 143,072 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Barclays PLC increased its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 187.6% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 219,331 shares of the biotechnology company's stock after buyingDecember 28, 2024 | marketbeat.comAurinia Pharmaceuticals laying off dozens in Montgomery CountyDecember 24, 2024 | bizjournals.comState Street Corp Has $21.59 Million Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)State Street Corp grew its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 2.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,945,060 shares of the biotechnology company's stock after buyingDecember 24, 2024 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest UpdateAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 6,220,000 shares, a decline of 9.6% from the November 15th total of 6,880,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the days-to-cover ratio is presently 4.9 days.December 15, 2024 | marketbeat.comInsiders Are Loving These 6 Stocks Right NowDecember 15, 2024 | 247wallst.comAurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to "Buy" at StockNews.comStockNews.com cut shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Friday.December 13, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 89,940 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Charles Schwab Investment Management Inc. grew its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 13.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 744,050 shares ofDecember 13, 2024 | marketbeat.comImplied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock OptionsDecember 10, 2024 | msn.comWhile institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownershipDecember 6, 2024 | finance.yahoo.comPDT Partners LLC Has $2.21 Million Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)PDT Partners LLC lifted its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 76.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 301,553 shares of the biotechnology company's stock after acquiring anDecember 1, 2024 | marketbeat.comAlgert Global LLC Sells 65,791 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Algert Global LLC lowered its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 33.9% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 128,013 shares of the biotechnology company's stock after selling 65,791 shares durNovember 30, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Invests $3.33 Million in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 454,259 shares of the biotechnolNovember 25, 2024 | marketbeat.comPositive Outlook for Aurinia Pharmaceuticals Boosted by Favorable Lupus Nephritis GuidelinesNovember 22, 2024 | markets.businessinsider.comAurinia Pharmaceuticals Celebrates New Lupus Nephritis GuidelinesNovember 19, 2024 | markets.businessinsider.comAurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus NephritisNovember 18, 2024 | financialpost.comAurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus NephritisNovember 18, 2024 | businesswire.comGSA Capital Partners LLP Sells 102,373 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)GSA Capital Partners LLP cut its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 44.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 125,645 shares of the bioteNovember 17, 2024 | marketbeat.comAurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024November 16, 2024 | markets.businessinsider.comAurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024November 15, 2024 | businesswire.comAurinia Pharmaceuticals Engages at London ConferenceNovember 15, 2024 | markets.businessinsider.comAurinia to Participate in Jefferies London Healthcare ConferenceNovember 14, 2024 | businesswire.comInsider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Director Sells 4,557 Shares of StockNovember 13, 2024 | insidertrades.comPositive Outlook on Aurinia Pharmaceuticals Amid Strong Financial Performance and Strategic Cost ManagementNovember 11, 2024 | markets.businessinsider.comResearch Analysts Offer Predictions for AUPH Q1 EarningsAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) - Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for shares of Aurinia Pharmaceuticals in a note issued to investors on Thursday, November 7th. Leerink Partnrs analyst J. Schwartz now antiNovember 11, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.comStockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday.November 8, 2024 | marketbeat.comAurinia Pharmaceuticals: A Potential Buyout Looms On The HorizonNovember 8, 2024 | seekingalpha.comAurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...November 8, 2024 | finance.yahoo.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 11% - Should You Buy?Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 11% - Should You Buy?November 7, 2024 | marketbeat.comAurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comShareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years agoNovember 2, 2024 | finance.yahoo.com Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address AUPH Media Mentions By Week AUPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AUPH News Sentiment▼0.350.60▲Average Medical News Sentiment AUPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AUPH Articles This Week▼103▲AUPH Articles Average Week Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KRYS News SWTX News BHVN News RXRX News PTCT News OGN News RARE News ALVO News RNA News ADMA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AUPH) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AUPH Stock Alerts